Pharming Group (NASDAQ:PHAR) Shares Up 9.5% - What's Next?

Key Points

• Pharming Group's stock surged 9.5% during mid-day trading, reaching a high of $14.35, despite a decline in trading volume of 24% from average levels.
• A number of brokerages have recently *adjusted their ratings*, with Zacks Research downgrading the stock from "strong-buy" to "hold," and the consensus target price set at $30.00.
• Pharming Group reported *better-than-expected earnings* in its quarterly results, with $0.06 EPS beating the consensus estimate of ($0.10), and revenue of $93.20 million exceeding analysts' expectations.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price shot up 9.5% during mid-day trading on Thursday . The stock traded as high as $13.70 and last traded at $14.35. 5,795 shares changed hands during trading, a decline of 24% from the average session volume of 7,641 shares. The stock had previously closed at $13.10.

Analysts Set New Price Targets

A number of brokerages recently commented on PHAR. Weiss Ratings reissued a "sell (d+)" rating on shares of Pharming Group in a research note on Wednesday, October 8th. Zacks Research lowered Pharming Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $30.00.

Pharming Group Trading Up 7.9%

The firm has a market cap of $968.05 million, a price-to-earnings ratio of -108.69 and a beta of 0.04. The company has a fifty day moving average price of $14.18 and a 200-day moving average price of $11.51. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The business had revenue of $93.20 million during the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, research analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.